Vivos, Inc. is a radiation oncology medical device company. The company is headquartered in Richland, Washington. The company went IPO on 2001-08-08. The firm has developed an Yttrium-90-based injectable Precision Radionuclide Therapy medical device to treat tumors in animals (IsoPet) and humans (RadioGel). Using the Company’s proprietary hydrogel technology, PRnT uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers. University veterinary hospitals use the IsoPet Solutions division to demonstrate animal cancers’ safety and therapeutic effectiveness. RadioGel is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor.
Follow-Up Questions
Vivos Inc의 CEO는 누구입니까?
Dr. Michael Korenko은 2009부터 회사에 합류한 Vivos Inc의 Chief Executive Officer입니다.
RDGL 주식의 가격 성능은 어떻습니까?
RDGL의 현재 가격은 $0.0788이며, 전 거래일에 decreased 0% 하였습니다.
Vivos Inc의 주요 사업 주제나 업종은 무엇입니까?
Vivos Inc은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
